Canaccord analyst Caitlin Cronin lowered the firm’s price target on Smith & Nephew to $32 from $35 and keeps a Hold rating on the shares. The firm updated its model ahead of Q1 results.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNN:
- Smith+Nephew Sets 6 May Date for Q1 2026 Trading Update
- Smith & Nephew announces evidence for Cartiheal Agili-C Cartilage Repair
- Smith & Nephew Grants Nil‑Cost RISE Share Plan Awards to Senior Leadership
- Smith & Nephew: Entering a Faster Growth Phase with Re-Rating Potential on Conservative Guidance
- Smith & Nephew Discloses Board Role Expansion for Senior Independent Director Designate